Plasma Clozapine, Norclozapine, and the Clozapine: Norclozapine Ratio in Relation to Prescribed Dose and Other Factors: Data From a Therapeutic Drug Monitoring Service, 1993-2007

被引:141
作者
Couchman, Lewis [1 ]
Morgan, Phillip Edgar [1 ]
Spencer, Edgar Pathrose [2 ]
Flanagan, Robert James [1 ]
机构
[1] Kings Coll Hosp NHS Fdn Trust, Dept Clin Biochem, Toxicol Unit, London, England
[2] St Thomas Hosp, GSTS Pathol, Med Toxicol Lab, London, England
关键词
therapeutic drug monitoring; adherence; smoking habit; clozapine TDM; norclozapine; plasma; clozapine: norclozapine ratio; ATYPICAL ANTIPSYCHOTICS; SCHIZOPHRENIC-PATIENTS; N-DESMETHYLCLOZAPINE; SMOKING-CESSATION; CLINICAL PHARMACOKINETICS; LIQUID-CHROMATOGRAPHY; SERUM; CONSTIPATION; OLANZAPINE; CIPROFLOXACIN;
D O I
10.1097/FTD.0b013e3181dad1fb
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Therapeutic drug monitoring of plasma clozapine and of its principal plasma metabolite N-desmethylclozapine (norclozapine) (predose or "trough" sample) can help in monitoring adherence, in dose adjustment, and in minimizing the risk of toxicity. To obtain data to assist in the interpretation of analytical results, the results from a clozapine therapeutic drug monitoring service, 1993-2007, have been audited. There were 104,127 samples from 26,796 patients [18,750 (70%) men aged at time of first sample (median, range) 34 (10-89) years, and 7763 (30%) female aged 38 (12-90) years]. Clozapine was not detected (plasma concentration <0.01 mg/L) in 1.5% of samples (prescribed clozapine dose up to 900 mg/d). Plasma clozapine was either below 0.35 mg/L or greater than 0.60 mg/L in 42.5% and 28.4% of samples, respectively; in 0.4% samples plasma clozapine was 2.0 mg/L or more. Although plasma clozapine was broadly related to prescribed dose, there was much variation: 1.2% of samples had plasma clozapine >1.0 mg/L at prescribed clozapine doses up to 150 mg/d (76.2% < 0.35 mg/L), whereas 23.3% of samples had plasma clozapine < 0.35 mg/L at doses of 850 mg/d and over (18.0% > 1.0 mg/L). The highest plasma clozapine and norclozapine concentrations encountered were 4.95 and 2.45 mg/L, respectively. Although the median plasma clozapine: norclozapine ratio was 1.25 at plasma clozapine concentrations < 0.35 mg/L, the median ratio was 2.08 at plasma clozapine concentrations > 1.0 mg/L. Data (median, 10th-90th percentile) for both clozapine and norclozapine by prescribed clozapine dose band are useful in assessing partial adherence. Analysis of the plasma clozapine: norclozapine ratio by clozapine concentration provides clear evidence that clozapine N-demethylation becomes saturated at higher plasma clozapine concentrations and adds urgency to the requirement for dose adjustment should smoking habit change. A clozapine: norclozapine ratio greater then 2 suggests either a nontrough sample, or that clozapine N-demethylation has become saturated.
引用
收藏
页码:438 / 447
页数:10
相关论文
共 62 条
[1]  
[Anonymous], 2001, Guidance for industry, bioanalytical method validation
[2]  
[Anonymous], 2009, Schizophrenia: Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care
[3]   Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia [J].
Barnett, A. H. ;
Mackin, P. ;
Chaudhury, I. ;
Farooqi, A. ;
Gadsby, R. ;
Heald, A. ;
Hill, J. ;
Millar, H. ;
Peveler, R. ;
Rees, A. ;
Singh, V. ;
Taylor, D. ;
Vora, J. ;
Jones, P. B. .
JOURNAL OF PSYCHOPHARMACOLOGY, 2007, 21 (04) :357-373
[4]   Ciprofloxacin Strongly Inhibits Clozapine Metabolism Two Case Reports [J].
Brouwers, E. E. M. ;
Sohne, M. ;
Kuipers, S. ;
van Gorp, E. C. M. ;
Schellens, J. H. M. ;
Koks, C. H. W. ;
Beijnen, J. H. ;
Huitema, A. D. R. .
CLINICAL DRUG INVESTIGATION, 2009, 29 (01) :59-63
[5]   Clozapine toxicity in smoking cessation and with ciprofloxacin [J].
Brownlowe, Katherine ;
Sola, Christopher .
PSYCHOSOMATICS, 2008, 49 (02) :176-176
[6]   CLINICAL PHARMACOKINETICS OF CLOZAPINE IN CHRONIC-SCHIZOPHRENIC PATIENTS [J].
CHENG, YF ;
LUNDBERG, T ;
BONDESSON, U ;
LINDSTROM, L ;
GABRIELSSON, J .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 34 (05) :445-449
[7]   CYP-mediated clozapine interactions: How predictable are they? [J].
Chetty, Manoranjenni ;
Murray, Michael .
CURRENT DRUG METABOLISM, 2007, 8 (04) :307-313
[8]   Optimal dosing of atypical antipsychotics in adults: A review of the current evidence. [J].
Citrome, L ;
Volavka, J .
HARVARD REVIEW OF PSYCHIATRY, 2002, 10 (05) :280-291
[9]  
Clinical and Laboratory Standards Institute, 2004, EP05A2 CLIN LAB STAN
[10]   A retrospective evaluation of the impact of total smoking cessation on psychiatric inpatients taking clozapine [J].
Cormac, I. ;
Brown, A. ;
Creasey, S. ;
Ferriter, M. ;
Huckstep, B. .
ACTA PSYCHIATRICA SCANDINAVICA, 2010, 121 (05) :393-397